BACKGROUND: MYC is an oncogenic driver of development and progression in triple-negative breast cancer (TNBC). Ornithine decarboxylase, the rate-limiting enzyme in polyamine metabolism, is a transcriptional target of MYC. We therefore hypothesized that a plasma polyamine signature may be predictive of TNBC development and progression. METHODS: Using liquid chromatography mass spectrometry, polyamine levels were determined in plasma samples from newly diagnosed patients with TNBC (n = 87) and cancer-free controls (n = 115). Findings were validated in plasma samples from an independent prospective cohort of 54 TNBC, 55 estrogen receptor negative (ER-) and progesterone receptor negative (PR-) and HER2 positive (HER2+), and 73 ER+ case patients, and 30 cancer-free control subjects. Gene expression data and clinical data for 921 and 2359 breast cancer tumors were obtained from The Cancer Genome Atlas repository and the Oncomine database, respectively. Relationships between plasma diacetylspermine (DAS) and tumor spermine synthase (SMS) mRNA expression with metastasis-free survival and overall survival were determined using Cox proportional hazard models; Fisher exact tests were used to assess risk of distant metastasis in relation to tumor SMS mRNA expression. RESULTS: An increase in plasma DAS, a catabolic product of spermine mediated through SMS, was observed in the TNBC subtype of breast cancer. Plasma levels of DAS in TNBC associated with increased risk of metastasis (plasma DAS value ≥ 1.16, hazard ratio = 3.06, 95% confidence interval [CI] = 1.15 to 8.13, two-sided P = .03). SMS mRNA expression in TNBC tumor tissue was also found to be predictive of poor overall survival (top 25th percentile hazard ratio = 2.06, 95% CI = 1.04 to 4.08, one-sided P = .04) and increased risk of distant metastasis in TNBC (comparison of lowest SMS quartile [reference] to highest SMS quartile relative risk = 1.90, 95% CI = 0.97 to 4.06, one-sided Fisher exact test P=.03). CONCLUSIONS: Metabolomic profiling identified plasma DAS as a predictive marker for TNBC progression and metastasis.
BACKGROUND: MYC is an oncogenic driver of development and progression in triple-negative breast cancer (TNBC). Ornithine decarboxylase, the rate-limiting enzyme in polyamine metabolism, is a transcriptional target of MYC. We therefore hypothesized that a plasma polyamine signature may be predictive of TNBC development and progression. METHODS: Using liquid chromatography mass spectrometry, polyamine levels were determined in plasma samples from newly diagnosed patients with TNBC (n = 87) and cancer-free controls (n = 115). Findings were validated in plasma samples from an independent prospective cohort of 54 TNBC, 55 estrogen receptor negative (ER-) and progesterone receptor negative (PR-) and HER2 positive (HER2+), and 73 ER+ case patients, and 30 cancer-free control subjects. Gene expression data and clinical data for 921 and 2359 breast cancer tumors were obtained from The Cancer Genome Atlas repository and the Oncomine database, respectively. Relationships between plasma diacetylspermine (DAS) and tumorspermine synthase (SMS) mRNA expression with metastasis-free survival and overall survival were determined using Cox proportional hazard models; Fisher exact tests were used to assess risk of distant metastasis in relation to tumor SMS mRNA expression. RESULTS: An increase in plasma DAS, a catabolic product of spermine mediated through SMS, was observed in the TNBC subtype of breast cancer. Plasma levels of DAS in TNBC associated with increased risk of metastasis (plasma DAS value ≥ 1.16, hazard ratio = 3.06, 95% confidence interval [CI] = 1.15 to 8.13, two-sided P = .03). SMS mRNA expression in TNBC tumor tissue was also found to be predictive of poor overall survival (top 25th percentile hazard ratio = 2.06, 95% CI = 1.04 to 4.08, one-sided P = .04) and increased risk of distant metastasis in TNBC (comparison of lowest SMS quartile [reference] to highest SMS quartile relative risk = 1.90, 95% CI = 0.97 to 4.06, one-sided Fisher exact test P=.03). CONCLUSIONS: Metabolomic profiling identified plasma DAS as a predictive marker for TNBC progression and metastasis.
Authors: Sharon J Pitteri; Karen S Kelly-Spratt; Kay E Gurley; Jacob Kennedy; Tina Busald Buson; Alice Chin; Hong Wang; Qing Zhang; Chee-Hong Wong; Lewis A Chodosh; Peter S Nelson; Samir M Hanash; Christopher J Kemp Journal: Cancer Res Date: 2011-06-08 Impact factor: 12.701
Authors: Amaia Zabala-Letona; Amaia Arruabarrena-Aristorena; Natalia Martín-Martín; Sonia Fernandez-Ruiz; James D Sutherland; Michelle Clasquin; Julen Tomas-Cortazar; Jose Jimenez; Ines Torres; Phong Quang; Pilar Ximenez-Embun; Ruzica Bago; Aitziber Ugalde-Olano; Ana Loizaga-Iriarte; Isabel Lacasa-Viscasillas; Miguel Unda; Verónica Torrano; Diana Cabrera; Sebastiaan M van Liempd; Ylenia Cendon; Elena Castro; Stuart Murray; Ajinkya Revandkar; Andrea Alimonti; Yinan Zhang; Amelia Barnett; Gina Lein; David Pirman; Ana R Cortazar; Leire Arreal; Ludmila Prudkin; Ianire Astobiza; Lorea Valcarcel-Jimenez; Patricia Zuñiga-García; Itziar Fernandez-Dominguez; Marco Piva; Alfredo Caro-Maldonado; Pilar Sánchez-Mosquera; Mireia Castillo-Martín; Violeta Serra; Naiara Beraza; Antonio Gentilella; George Thomas; Mikel Azkargorta; Felix Elortza; Rosa Farràs; David Olmos; Alejo Efeyan; Juan Anguita; Javier Muñoz; Juan M Falcón-Pérez; Rosa Barrio; Teresa Macarulla; Jose M Mato; Maria L Martinez-Chantar; Carlos Cordon-Cardo; Ana M Aransay; Kevin Marks; José Baselga; Josep Tabernero; Paolo Nuciforo; Brendan D Manning; Katya Marjon; Arkaitz Carracedo Journal: Nature Date: 2017-06-28 Impact factor: 49.962
Authors: Johannes F Fahrmann; Leonidas E Bantis; Michela Capello; Ghislaine Scelo; Jennifer B Dennison; Nikul Patel; Eunice Murage; Jody Vykoukal; Deepali L Kundnani; Lenka Foretova; Eleonora Fabianova; Ivana Holcatova; Vladimir Janout; Ziding Feng; Michele Yip-Schneider; Jianjun Zhang; Randall Brand; Ayumu Taguchi; Anirban Maitra; Paul Brennan; C Max Schmidt; Samir Hanash Journal: J Natl Cancer Inst Date: 2019-04-01 Impact factor: 13.506
Authors: Bas Kreike; Marieke van Kouwenhove; Hugo Horlings; Britta Weigelt; Hans Peterse; Harry Bartelink; Marc J van de Vijver Journal: Breast Cancer Res Date: 2007 Impact factor: 6.466
Authors: Johannes F Fahrmann; Ehsan Irajizad; Makoto Kobayashi; Jody Vykoukal; Jennifer B Dennison; Eunice Murage; Ranran Wu; James P Long; Kim-Anh Do; Joseph Celestino; Karen H Lu; Zhen Lu; Robert C Bast; Samir Hanash Journal: Cancers (Basel) Date: 2021-02-22 Impact factor: 6.639
Authors: Yihui Chen; Michela Capello; Mayrim V Rios Perez; Jody V Vykoukal; David Roife; Ya'an Kang; Laura R Prakash; Hiroyuki Katayama; Ehsan Irajizad; Alia Fleury; Sammy Ferri-Borgogno; Dodge L Baluya; Jennifer B Dennison; Kim-Anh Do; Oliver Fiehn; Anirban Maitra; Huamin Wang; Paul J Chiao; Matthew H G Katz; Jason B Fleming; Samir M Hanash; Johannes F Fahrmann Journal: Mol Metab Date: 2021-12-28 Impact factor: 7.422
Authors: Renee C Geck; Jackson R Foley; Tracy Murray Stewart; John M Asara; Robert A Casero; Alex Toker Journal: J Biol Chem Date: 2020-03-05 Impact factor: 5.157
Authors: Johannes F Fahrmann; Amanda R Wasylishen; Carolina R C Pieterman; Ehsan Irajizad; Jody Vykoukal; Eunice Murage; Ranran Wu; Jennifer B Dennison; Hansini Krishna; Christine B Peterson; Guillermina Lozano; Hua Zhao; Kim-Anh Do; Daniel M Halperin; Sunita K Agarwal; Jenny E Blau; Jaydira Del Rivero; Naris Nilubol; Mary F Walter; James M Welch; Lee S Weinstein; Menno R Vriens; Rachel S van Leeuwaarde; Mark J C van Treijen; Gerlof D Valk; Nancy D Perrier; Samir M Hanash Journal: J Clin Endocrinol Metab Date: 2021-11-19 Impact factor: 6.134